.png)
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Precision Antibody prides itself in developing application-specific antibodies with high specificity and sensitivity. In the field of biomarkers, the specificity and sensitivity of reagents are key performance characteristics for a successful assay development necessary for clinical application. With over 20 years of experience and expertise, Precision Antibody (PA) understands these challenges, offering a “one-stop shop” for many clients needing comprehensive application-specific antibody development services, from initial antigen design and immunization to antibody development, characterization, sequencing, and purification. Thanks to our ability to deliver antibodies that work in the intended assay in 60 days, PA has become a preferred vendor for many major pharmaceutical, biotech, and diagnostic companies, including many academic and government institutions, to fulfill their therapeutic and diagnostic needs.
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
DetermaIO, a gene expression assay, assesses components of the Tumor Immune Micro-Environment (TIME) to determine the likelihood of benefit from Immune Checkpoint Inhibitor therapy.
Oncocyte believes in democratizing our laboratory offerings via widely distributed kits and is developing a TIME assessment kit for research use.
Explore further at www.oncocyte.com.
Veranex is the leading end-to-end service provider for medical device companies. Through our proven expertise and resources, we help medtech leaders accelerate innovations to market. Our purpose-built, multi-disciplinary global teams pull from an unparalleled breadth and depth of experience to anticipate challenges and proactively find solutions at every stage of the development-to-commercial-launch continuum. Together, we can advance innovation to improve patient outcomes.
Q2 Solutions is a leading global clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. Q2 Solutions uses global experience, innovation and scientific expertise to transform science and data into medical insights that turn hope into help. A joint venture of IQVIA and Quest Diagnostics, Q2 Solutions leverages each parent organization’s clinical trials laboratory capabilities and treats each sample as if a life depends on it.
